Antiretroviral treatment of HIV infected adults
- 22 June 2006
- Vol. 332 (7556) , 1489
- https://doi.org/10.1136/bmj.332.7556.1489
Abstract
Introduction It has been about 10 years since the first report that three drug combination antiretroviral therapy can durably suppress HIV replication.1 Subsequent studies have confirmed that when used appropriately highly active antiretroviral therapy (see box 1) can suppress viral replication to such low levels that the virus is unable to generate drug resistance mutations. Theoretically, once this level of viral suppression is achieved, treatment should work indefinitely, and the long term risk of morbidity and morality related to HIV associated immunodeficiency becomes negligible. Experience to date suggests that lifelong suppression of HIV is feasible. This review is aimed at informing clinicians about the current management of HIV infection. Authoritative and continuously updated reviews are available on the web (for example, the US Department of Health and Human Services treatment guidelines at www.hivatis.org); this review does not attempt to exhaustively summarise the literature or to provide guidance to clinicians with expertise in HIV. Rather, I summarise those issues that are likely to confront clinicians, including clinicians who do not routinely treat people infected with HIV.Keywords
This publication has 46 references indexed in Scilit:
- Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIVNew England Journal of Medicine, 2006
- Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort studyThe Lancet, 2002
- A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2002
- Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirPublished by Elsevier ,2002
- Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug TherapyJAMA, 2001
- Metabolic effects of indinavir in healthy HIV-seronegative menAIDS, 2001
- Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable ViremiaNew England Journal of Medicine, 2001
- Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failureAIDS, 2000
- Adverse effects of antiretroviral therapyThe Lancet, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999